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Abstract: Hyperglycaemia is a common complication of prematurity and stress in neonatal intensive care 
units (NICUs). It has been linked to worsened outcomes and mortality. There is currently no universally 
accepted best practice glycaemic control method, with many protocols lacking patient specificity and 
relying heavily on clinical judgment. The result is persistent hypoglycaemia and poor control. This 
research presents the virtual trial design and optimisation of a stochastic targeted (STAR) approach to 
improve performance and reduce hypoglycaemia. Clinically validated virtual trials based on NICU 
patient data (N = 61 patients, 7006 hours) are used to develop and optimise a STAR protocol that 
improves on current STAR-NICU performance and reduce hypoglycaemia. Five approaches are used to 
maximize the stochastic range of BG outcomes within 4.0-8.0mmol/L, and are designed based on an 
overall cohort risk to provide clinically specified risk (5%) of BG above or below a clinically specified 
level. The best protocol placed the 5th percentile BG outcome for an intervention on 4.0mmol/L band. 
The optimised protocol increased %BG in the 4.0-8.0mmol/L band by 7% and the incidence of 
BG<2.6mmol/L by 1 patient (50%). Significant intra- and inter- patient variability reduced possible 
performance gains, indicating a need for patient-specific or sub-cohort specific approaches to manage 
variability.   
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1. INTRODUCTION 
Hyperglycaemia is a common complication of prematurity in 
the neonatal intensive care unit (NICU) resulting from 
underdeveloped glucose regulation systems and a hormone-
based stress response (Barker and Rutter, 1996). It has been 
linked to worsened outcomes and mortality (Hays et al., 
2006, Heimann et al., 2007), increased ventilator dependence 
and clinical length of stay (Alaedeen et al., 2006), and other 
complications (Alaedeen et al., 2006, Hays et al., 2006). 
Hypoglycaemia in this cohort is also linked to adverse 
outcomes and death (Lucas et al., 1988). 
There is currently no best practice method or target for 
glycaemic control in pre-term infants. Blood glucose (BG) 
levels are often controlled by varying nutritional input, which 
may not be ideal for infant growth (Thabet et al., 2003). To 
date, fixed or ad hoc protocols are often utilised, which lack 
patient specificity and rely extensively on clinical judgement. 
Hence, the few larger trials have experienced problems with 
persistent hypoglycaemia and poor control (Beardsall et al., 
2008). However, using insulin to treat hyperglycaemia has 
been associated with positive outcomes (Beardsall et al., 
2008, Binder et al., 1989, Collins et al., 1991, Kanarek et al., 
1991, Thabet et al., 2003).  
Model-based control has shown benefit in the NICU and 
adult ICU. These methods titrate care by identifying patient-
specific insulin sensitivity over time.  In contrast, fixed 
protocols assume constant insulin sensitivity across all 
patients, and weight-based protocols assume a patient-
specific insulin sensitivity that remains constant over the 
entire treatment period (Le Compte et al., 2011). Neither 
assumption is accurate, resulting in poor control and 
excessive hypoglycaemia (Le Compte et al., 2010b).  
Stochastic TARgeting (STAR) is a model-based accurate 
glycaemic control (AGC) framework that directly quantifies 
inter- and intra- patient variability by forecasting a range of 
possible BG outcomes based on current patient-specific 
metabolic state ( Le Compte et al., 2010b). It overlaps this 
range with a  BG target band to maximise safety and the 
likelihood of BG in band. This research presents the virtual 
trial design optimisation of a STAR-NICU control approach. 
The goals are to reduce hypoglycaemia and improve 
performance  of an existing clinically applied NICU 
controller (Le Compte et al., 2009). 
2. METHODS 
Optimisation of the STAR approach for the NICU used 
clinically validated virtual trial methods (Chase et al., 2010) 
and virtual patients created from NICU clinical data.  
2.1 System model 
A clinically validated Neonatal Intensive Care Insulin-
Nutrition-Glucose (NICING) metabolic model is used (Le 
Compte et al., 2010a):  
 
 
 
     
 
?̇? = −𝑝𝐺𝐺(𝑡) −  𝑆𝐼𝐺(𝑡) 𝑄(𝑡)1 +  𝛼𝐺𝑄(𝑡)                  +𝑃(𝑡) +  𝐸𝐺𝑃 ∗ 𝑚𝑏𝑜𝑑𝑦 − 𝐶𝑁𝑆 ∗ 𝑚𝑏𝑟𝑎𝑖𝑛
𝑉𝑔,𝑓𝑟𝑎𝑐(𝑡) ∗ 𝑚𝑏𝑜𝑑𝑦           (1) 
𝐼̇ =  −  𝑛𝐿𝐼(𝑡)1 +  𝛼𝐼𝐼(𝑡) − 𝑛𝐾𝐼(𝑡) − 𝑛𝐼�𝐼(𝑡) − 𝑄(𝑡)�+  𝑢𝑒𝑥(𝑡)
𝑉𝐼,𝑓𝑟𝑎𝑐 ∗ 𝑚𝑏𝑜𝑑𝑦+ (1 − 𝑥𝐿) 𝑢𝑒𝑛(𝐺)𝑉𝐼,𝑓𝑟𝑎𝑐 ∗ 𝑚𝑏𝑜𝑑𝑦                  (2) 
?̇? =  𝑛𝐼�𝐼(𝑡) − 𝑄(𝑡)� −  𝑛𝐶 𝑄(𝑡)1 +  𝛼𝐺𝑄(𝑡)                        (3) 
?̇?1 =  −𝑑1𝑃1 + 𝑃(𝑡)                                                              (4) 
?̇?2 =  −min(𝑑2𝑃2,𝑃𝑚𝑎𝑥) + 𝑑1𝑃1                                       (5) 
𝑃(𝑡) = min(𝑑2𝑃2,𝑃𝑚𝑎𝑥) + 𝑃𝑁(𝑡)                                    (6) 
𝑢𝑒𝑛 =  IB𝑒−𝑘𝐼𝑢𝑒𝑥𝑉𝐼                                                                     (7) 
 Insulin sensitivity (𝑆𝐼) is identified hourly and describes 
patient-specific time-varying metabolic state (Le Compte et 
al., 2011), enabling patient-specific control. Table 1 defines 
the other parameters. Notably, no saturation is applied  for 
neonates (in Equation (1) ∝𝐺= 0) (Farrag et al., 1997) . 
2.2 Control Protocol Optimisation 
2.2.1 Stochastic Targeted Control 
As shown in Figure 1 STAR utilises the current identified  𝑆𝐼  
to describe the current metabolic state of the neonate. A 
stochastic forecasting model ( Le Compte et al., 2010b) then 
predicts the range of possible changes in 𝑆𝐼  over the coming 
intervention interval. From this range of 𝑆𝐼  values a range of  
resulting BG outcomes can be calculated for a given insulin 
intervention. The aim is to overlap these predicted BG 
outcomes with a clinically specified target range to maximise 
the likelihood of the BG levels in that range. In this study, 
measurement intervals of 4 hours were chosen, due to 
restrictions arising from the very low blood volume of 
premature neonates. 
2.2.2 Protocol Optimisation 
The existing STAR NICU controller (Le Compte et al., 2009) 
checks  insulin doses until the 50th  percentile BG prediction 
is 6.0 mmol/L (Le Compte et al., 2011). It then checks that 
95% of predicted BG levels ≥ 4.0 mmol/L, and reduces 
insulin if required. To improve this approach, the following 
control approaches were tested:  
• PROTOCOL 1: Select insulin infusion rate that causes 
the 5th percentile BG prediction to be within a tolerance 
of a clinically specified lower BG limit. As with the 
current protocol, this limits the risk of BG less than this 
lower target to 5%, but does not target the median result. 
• PROTOCOL 2: Select the insulin infusion rate placing 
the 95th percentile BG prediction within a tolerance of an 
upper BG limit. This approach is more aggressive and 
does not consider a lower limit. 
• PROTOCOL 3: As per Protocol 1 to give a total 
recommended insulin volume for the measurement 
interval (4 hours). Then give half of the insulin as a bolus 
for the first hour, and give the rest over the remaining 3  
hours as an infusion.  
• PROTOCOL 4: As per Protocol 1, but giving an insulin 
bolus that yields a 5th percentile BG on 4.0 mmol/L in 
the first hour, followed by an  infusion for the remaining 
Table 1: Glucose-insulin metabolic model variable definition 
Variable Description Values 
G Blood glucose level (mmol/L) 
I Plasma insulin concentration (mU/L) 
Q Interstitial insulin 
concentration 
(mU/L) 
pG Endogenous glucose 
clearance 
0.0030 (min−1) 
αG Saturation parameter for 
insulin mediated glucose 
removal 
0 (L/mU) 
αI Saturation parameter for 
plasma  insulin clearance 
0.0017 (L/mU) 
SI Insulin sensitivity (L/mU/min) 
EGP Endogenous glucose 
production 
0.0284 
(mmol/min) 
CNS Central nervous system 
glucose uptake 
0.088 
(mmol/min) 
P(t) Glucose appearance in plasma 
from dextrose intake 
(mmol/min) 
PN Parenteral Nutrition (mmol/min) 
Pmax Maximal glucose flux from 
gut to plasma 
6.11 
(mmol/min) 
P1 Glucose level in stomach (mmol) 
P2 Glucose level in gut (mmol) 
VG Plasma glucose distribution 
volume 
0.5961 (L) 
kI Interstitial insulin transport 
rate 
0.1 (min−1) 
IB Endogenous insulin 
production 
15 [mU/L/min] 
nI Rate of transport between 
plasma and interstitial insulin 
compartments 
0.003 (min-1)  
nK Renal insulin clearance 0.150(min−1) 
nL Hepatic insulin clearance 1 (min−1) 
nC Interstitial insulin degradation 0.003 (min−1) 
𝒙𝑳 First-pass hepatic insulin 
clearance 
0.67 
uex(t) Exogenous insulin (mU/min) 
uen(t) Endogenous insulin 
production 
(mU/min) 
VI Plasma insulin distribution 
volume 
0.0450 (L) 
d1 Glucose absorption rate from 
stomach 
0.0347 (min−1) 
d2 Glucose absorption rate from 
gut 
0.0069 (min−1) 
D(t) Dextrose intake (mmol/min) 
𝒎𝒃𝒐𝒅𝒚 Body mass (kg) 
𝒎𝒃𝒓𝒂𝒊𝒏 Brain mass (14% 𝒎𝒃𝒐𝒅𝒚) (kg) 
 
 
     
 
time period so that the 5th percentile BG  remains on 4.0 
mmol/L at the end of the entire measurement interval .  
• PROTOCOL 5: As per Protocol 4, but giving an insulin 
infusion, instead of a bolus, over the first hour. 
Protocols 3, 4 and 5 allow more aggressive control where 
certainty is the greatest - in the first hour, immediately after 
𝑆𝐼  is identified. In all protocols, if BG< 4.0 mmol/L no 
insulin is given to for safety.  An upper limit is applied to the 
amount the insulin rate can increase between treatments to 
ensure control is not compromised by glucose meter error, or 
short perturbations from the neonate's normal glycaemic 
state. No attempt was made to regulate nutritional inputs, 
which were left to clinical choice. 
To improve the best protocol a sensitivity analysis was 
carried out on the limit on the increase in insulin rate 
between treatments. Limits on the rate of insulin change can 
limit control over-response to short-term changes in observed 
sensitivity to insulin caused by measurement device error or 
rapid fluctuations in patient condition.The limit used by the 
STAR-NICU controller is set to a maximum 0.03 U/kg/hr 
increase in insulin infusion. The effect of higher and lower 
limits was investigated, as well as variable BG defined limits. 
2.3 Virtual Patient Data  
The virtual cohort consisted of 25 patients that received 
insulin with no particular protocol, and  a further 36 using 
new clinical data  from short term (24 hour)  and long  
STAR-NICU trials (Le Compte et al., 2011). This clinical 
data was derived from extremely low birth weight (<1.0kg) 
and very low birth weight neonates (<1.5kg). Cohort 
summary statistics are in Table 2. Notably, two of these 
patients started hypoglycaemic (BG< 2.6 mmol/L).  
2.4 Analyses and Performance Metrics 
Results were compared against to the existing protocol. The 
following performance metrics were used: 
• SAFETY: number of severe hypoglycaemic events 
(BG<2.6 mmol/L), and hypoglycaemia (%BG<4.0 
mmol/L and %BG<3.0mmol/L ).  
• PERFORMANCE: %BG within the 4.0-8.0 mmol/L 
band, and hyperglycaemia ( BG>10.0 mmol/L). 
3. RESULTS 
3.1 Control Protocol Results 
Table 3 summarises the results for all 5 protocols. 
Performance metrics showed that Protocol 1 was the 
optimum, balancing desired reductions in hyperglycaemia 
with reduced hypoglycaemic events. Protocol 2 was the most 
aggressive by design, and thus had significant 
hypoglycaemia. Protocols 3-5 showed little gain maximising 
certainty, and require more clinical effort. 
Figure 2 shows the cumulative distributions for each 
protocol. The relatively small differences between protocols 
is attributed to high inter- and intra- patient variability, 
dominating the ability to control BG. 
3.2 Sensitivity Analysis on Protocol 1 
Figure 3 presents the sensitivity analysis on the limit on the 
increase in insulin. As larger changes in insulin were 
permitted, improved time in band was possible, but the 
incidence of severe hypoglycaemia was increased. Thus, 
increasing the limit increased hypoglycaemia without 
significantly decreasing hyperglycaemia.  
Table 4 presents results from determining the allowable 
increase in insulin with BG level and indicates that setting 
insulin change limits based on current BG levels is effective . 
Limiting the increase in insulin rate to 0.015 U/kg/hr for BG< 
6mmol/L, to 0.03 U/kg/hr for 6.0≤BG≤10 mmol/L, and to 
0.06 U/kg/hr for BG>10 mmol/L provides the best 
combination to improve performance and safety.  
3.3 Final Protocol 
 
The analysis resulted in the development of a final controller 
defined: 
• Stochastic Targeting to place the lower 5th percentile of 
BG predictions on the lower band limit of 4.0mmol/L. 
• Blood glucose level determined limits on the increase in 
 
Figure 1: Adaptive control methodology. Distributions of 
𝑺𝑰 (𝒕𝒏+𝟏) and resulting BG forecast are illustrated 
Table 2: Clinical patient summary statistics.  
 Short-term (N=8) Long-term (N=28) Retrospective (N=25) 
 Median [IQR] Median [IQR] Median [IQR] 
Gestational age at birth (weeks) 25.6 [24.9 - 26.4] [25.4 [25.0 - 26.8] 26.6 [25.4 - 27.7] 
Weight at birth (grams) 745 [681 - 814] 760 [601 - 925] 845 [800 - 904] 
Age at start of trial (days) 6.6 [3.6 - 7.7] 3.6 [1.5 - 6.4] n/a 
 
 
     
 
insulin between treatments: if BG< 6.0mmol/L the insulin 
limit is 0.015 U/kg/hr;  if 6.0<BG<10 mmol/L the limit is 
0.03 U/kg/hr; if BG>10 mmol/L the limit is 0.06 U/kg/hr. 
• As a safety precaution, for BG <4.0 mmol/L no insulin 
therapy is given. 
The final protocol results are presented in Table 5 for the 36 
STAR-NICU patients in comparison to clinical results using 
the previous generation controller. Virtual trials with 3 hour 
measurement intervals and the clinical measurement intervals 
are also shown. The new STAR-NICU protocol reduces 
hypoglycaemia and %BG<4.0, with  slightly improved 
performance.  
It is important to note that the clinical data averages 3 hourly 
measurement with significant variability between patients. 
Hence, the 3 hourly results are a better direct comparison to 
clinical data. These results show a 7% improvement in 
performance, and a 50% reduction in hypoglycaemic 
patients. 
4. DISCUSSION 
Virtual trials to develop a STAR protocol for use in the 
NICU improves on performance of the current STAR-NICU 
protocol, which has a very different balance of safety and 
performance in its design. This new protocol uses stochastic 
targeting to place the 5th percentile of predicted BG 
outcomes on a lower limit of 4.0 mmol/L to maximize 
overlap between the range of possible BG outcomes and a 
clinically specified target band (4.0-8.0mmol/L).The 
maximum increase in insulin is limited based on BG level, so 
that as the risk of hypoglycaemia decreases, more aggressive 
insulin treatments can be utilised. This approach allows 
direct management, of hyper- and hypo- glycaemic risk. 
Table 5 shows that, for comparable measurement interval, 
the new protocol has a 7% improvement in time in band and 
lowered incidence of hypoglycaemia. This improvement is 
relatively small, a fact attributed to limitations caused by 
high inter- and intra- patient variability. Due to the large 
bandwidth of forecasted outcomes observed, it is evident that 
the existing controller also puts the 5th percentile BG on 4.0 
mmol/L most of the time, despite initially targeting the 50th 
percentile BG to 6.0mmol/L. The result is that the control 
protocols are effectively more similar than they are by 
 
Figure 2: BG cumulative distribution across entire cohort. 
The desired 4.0-8.0mmol/L band is outlined showing 
performance and safety bounds 
 
Figure 3: Sensitivity analysis on insulin increase limit, 
showing impact on the primary performance and safety. 
Table 3: Protocol comparison whole cohort re-sampled statistics  
 Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5 
Performance:      
Median BG [IQR] 6.59 
 [5.52 - 8.55] 
5.56 
[4.54 - 7.40] 
6.26 
 [5.33 - 8.00] 
6.50  
[5.46 - 8.25] 
6.65  
[5.56 - 8.61] 
% BG within 4.0 - 7.0 mmol/L 54.7 58.6 60.0 56.6 53.4 
% BG within 4.0 - 8.0 mmol/L 67.2 67.0 72.2 69.6 66.4 
%  BG > 10 mmol/L 15.9 10.2 13.0 13.9 16.6 
Safety:      
% BG < 4.0 mmol/L 2.50 12.56 2.84 2.70 2.39 
%  BG < 3.0 mmol/L 0.39 1.97 0.42 0.60 0.39 
Num patients* < 2.6 mmol/L 5 29 5 8 4 
Median Insulin Rate[IQR] 
(U/kg/hr) 
0.034 
[0.027 - 0.048] 
0.033 
[0.030 - 0.059] 
0.032 
[0.026 - 0.043] 
0.029 
[0.020 - 0.036] 
0.031 
[0.025 - 0.043] 
Median Glucose Rate[IQR] 
(mg/kg/min): 
8.0 
[6.1 - 9.2] 
8.0 
[6.1 - 9.2] 
8.0 
[6.1 - 9.2] 
8.0 
[6.1 - 9.2] 
8.0 
[6.1 - 9.2] 
* Not including the one patient that started low, but did not have subsequent BG<2.6mmol/L 
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definition. Thus most of the improvement is due to 
optimisation of targeting parameters, rather than of the 
control protocol itself.  
 The effect of patient variability, represented by the width of 
the 5th - 95th stochastic prediction band, can be seen in Figure 
4. The 5th percentile is almost always on 4.0 mmol/L, as set 
by the controller, but the 95th percentile can be up to 25 
mmol/L. The model BG curve, as expected, tracks between. 
This effect is much larger at higher blood glucose levels, 
where wide prediction bands in 𝑆𝐼  are magnified by high BG 
and large recommended insulin dosage. As expected, there 
are a few incidences where the model BG curve falls below 
the lower 5th percentile, which has a 5% chance of occurrence 
by definition. However, the upper 95th percentile is quite 
clearly over-conservative, and does not display the expected 
5% occurrence of  BG above this level. These results indicate 
a need for refinement of the stochastic models. 
Through the use of limits on the maximum change in insulin 
rate, some of the benefits in performance of other protocols 
were realised in Protocol 1. As seen in Figure 3, beyond the 
limit on the increase of insulin to around 0.045 U/kg/hr, the 
difference between median insulin rate and time in band 
statistics is much lower than that for limits between 0.015 to 
0.045 U/kg/hr.  This result suggests that the use of  limits 
below 0.045 U/kg/hr  moderates any hypoglycaemia due to 
sudden rises in 𝑆𝐼  Thus, BG dependeant limits on the increase 
in the insulin rate are effective at balancing  aggressive and 
safe control. 
An overall and significant outcome was a better 
understanding of the limitations of current models and the 
significant effect of patient variability on control performance 
for this cohort. Although some improvement in performance 
was achieved, they are unlikely to be clinically substantial. 
Table 4:BG defined limits on insulin (U/kg/hr)  
 For BG<6 limit 
0.015 U/kg/hr, 
else 0.03 U/kg/hr 
For 
BG<7limit 
0.015 U/kg/hr, 
else 0.03 
U/kg/hr 
For BG<7 limit 0.015 
U/kg/hr, else if 
BG>10 limit 0.06 
U/kg/hr, else 0.03 
U/kg/hr 
For BG<6 limit 
0.015 U/kg/hr, else 
if BG>9 limit 0.06 
U/kg/hr, else  0.03 
U/kg/hr 
For BG<6 limit 
0.015 U/kg/hr, else if 
BG>10 limit 0.06 
U/kg/hr, else 0.03 
U/kg/hr 
Performance:      
Median BG [IQR] 6.60 
[5.52 - 8.55] 
6.60 
[5.52 - 8.55] 
6.61 
[5.55 - 8.46] 
6.55 
[5.51 - 8.42] 
6.57 
[5.52 - 8.43] 
% BG within 4.0 - 8.0 
mmol/L 
67.30 67.30 67.96 68.44 68.19 
%  BG > 10 mmol/L 15.93 15.93 15.11 14.93 15.05 
Safety      
% BG < 4.0 mmol/L 2.32 2.32 2.25 2.45 2.38 
Num patients < 2.6 
mmol/L  
4 4 4 5 4 
* Not including the one patient that started low, but did not have subsequent BG<2.6mmol/L 
 
Figure 4: BG response over time with simulated forecast 
bands for a representative patient.  
Table 5: Comparison of Optimized Controller with Existing NICU Controller 
   NICU STAR 
Clinical Data 
Opti-STAR - 4 
hours (simulated) 
Opti-STAR - 3 
hours (simulated) 
Opti-STAR – clinical 
measurement 
interval 
Clinical Effort:     
Measurements/day [IQR] 8.1 [7.2-9.6] 6.7 [6.3-6.9] 8.5 [8.2-8.8] 8.1 [7.2-9.6] 
Performance:     
Median BG [IQR] 6.6 [5.5 - 8.2] 6.57 [5.52 - 8.41] 6.3 [5.31 - 8.09] 6.59 [5.45 - 8.53] 
% BG within 4.0 - 8.0 mmol/L 68.48 67.6 72.1 67.5 
%  BG > 10 mmol/L 12.51 17.7 14.3 16.0 
Safety:     
% BG < 4.0 mmol/L 3.67 2.19 2.1 2.54 
%  BG < 3.0 mmol/L 0.46 0.39 0.23 0.55 
Num patients < 2.6 mmol/L  4 3 2 2 
Median Insulin Rate[IQR] 
(U/kg/hr) 
0.034 
 [0.029 - 0.051] 
0.034  
[0.027 - 0.048] 
0.040 
 [0.030 - 0.052] 
0.043  
[0.032 - 0.057] 
Median Glucose Rate[IQR] 
(mg/kg/min): 
8.0 [6.5 - 9.3] 8.0 [6.1 - 9.2] 8.0 [6.1 - 9.2] 7.6 [5.3 - 9.3] 
0 50 100 150 200 250 300
0
5
10
15
20
25
BG
 (m
m
ol
/L
)
Time (hours)
Retrospective Patient 1
 
 
BG measurements 
Model BG
5th Percentile BG
95th Percentile BG
Comment [ID1]: These glucose rates 
appear to be different, however nutritional 
inputs weren’t altered  were they tied to 
measurement frequency ro similar? 
 
 
     
 
This outcome is attributed to the high level of inter- and intra- 
patient variability. However, the limitations of such 
variability on neonatal glycaemic control were still unknown.  
Figure 4, shows how control is severely limited by overly 
conservative bands, the 5th percentile BG forecast is almost 
always at 4 mmol/L. To achieve greater glycaemic control 
performance methods must be investigated to better capture 
patient-specific variation to mitigate this issue. 
Further limitations are present in the form of restrictions on 
the number of blood glucose measurements that can be taken 
in a set time period. Neonates have extremely limited blood 
volume, so the lower limit on measurement interval is 2 
hours, with clinical preference being 3-4 hours. Hence, the 
control protocols are optimised for 4 hourly intervals, 
although 3 hourly intervals gives better performance.  
5. CONCLUSIONS 
The main outcomes from this study were the optimisation of 
the NICU-STAR controller, and a greater understanding of 
the limitation of current control methods because of inter- 
and intra- patient variability. The control protocol optimised 
selected the insulin infusion rate that put the 5th percentile 
BG prediction on 4.0mmol/L. In addition, BG dependent 
limits on the increase in insulin rates was found to be an 
effective way to lower hyperglycaemia without increasing 
hypoglycaemia. It was found that the optimised controller 
outperformed the existing STAR-NICU controller by around 
7% in clinically validated virtual trials using 3 hourly 
measurement intervals, a result attributed to optimisation of 
control parameters, rather than specific differences in control 
methods. To further improve control, better quantification of  
inter- and intra- patient variability are required, as this 
variability limits the amount of insulin that can be safely 
administered, which sets the focus for next steps in this field. 
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Comment [ID2]: Most of this paragraph 
is presented in the discussion of Fig. 4, so 
can potentially have some space to spare... 
